Oliver Dorigo, MD, PhD, Director of the Stanford Gynecologic Oncology Clinical Care Program and Director of Stanford Obstetrics and Gynecology’s Division of Gynecologic Oncology provided an introduction to clinical trials for ovarian cancer patients. Dr. Dorigo discussed what clinical trials are, why they are important and how they work, the pros and cons of enrolling … Continued
The Consortium for Long-Term Survival — is bringing together research groups worldwide. These groups include survivors, patient advocates and advocacy groups, (not just researchers) with the goal of “FINDING THE KEY TO LONG-TERM SURVIVAL FOR ALL WOMEN.” RECRUITING NOW: 8+ year survivors, STAGE 3 or 4 ONLY, contact Giulia Fulci, gfulci@partners.org or 617-643-7261. View more … Continued
(May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought. In fact, it may be affected by effector T cells (cells that defend … Continued
(May 2, 2016) Research published last month in the International Journal of Cancer showed an unexpected finding: young women with irregular menstrual periods may be at higher risk of developing—and dying from—ovarian cancer later in life. The study provides the first evidence linking abnormally long cycles or missed periods to higher ovarian cancer risk. It … Continued
May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-‐affiliated scientists. Each team, consisting of researchers from different SU2C-‐supported “Dream Teams” or research programs, will receive a grant of $200,000 to support new research projects stemming … Continued
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-affiliated scientists. Each team, consisting … Continued
(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with HT use in the entire study population, and it … Continued
New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with HT use in the entire study population, and it appears to positively … Continued
Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that the results of this … Continued
Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that the results of this … Continued
April 11, 2016 – Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that … Continued
The Lancet has recently published an update to the progression-free survival (PFS) data of theICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial. ICON6 is designed to evaluate the safety and … Continued
Get email updates about research news, action alerts, and ways to join the fight.
